Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study.

DeaƱo RC, Glassner-Kolmin C, Rubenfire M, Frost A, Visovatti S, McLaughlin VV, Gomberg-Maitland M.

JAMA Intern Med. 2013 May 27;173(10):887-93. doi: 10.1001/jamainternmed.2013.319.

PMID:
23568223
2.
3.

[Is pulmonary hypertension diagnosed correctly and early enough? Highly relevant dilemma: incomplete diagnostic, inaccurate treatment].

Rosenkranz S.

Dtsch Med Wochenschr. 2013 Sep;138(37):1820. doi: 10.1055/s-0032-1329060. Epub 2013 Sep 4. German. No abstract available.

PMID:
24006160
4.

Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.

Farber HW, Miller DP, Meltzer LA, McGoon MD.

J Heart Lung Transplant. 2013 Nov;32(11):1114-22. doi: 10.1016/j.healun.2013.08.010. Epub 2013 Sep 10.

PMID:
24035189
5.

Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.

Small M, Piercy J, Pike J, Cerulli A.

Adv Ther. 2014 Feb;31(2):168-79. doi: 10.1007/s12325-014-0094-z. Epub 2014 Jan 22.

PMID:
24449285
6.

[Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation].

Kaemmerer H, Gorenflo M, Hoeper M, Huscher D, Ewert P, Pittrow D.

Dtsch Med Wochenschr. 2013 Jun;138(23):1247-52. doi: 10.1055/s-0033-1343189. Epub 2013 May 29. Review. German.

PMID:
23720182
7.

A pulmonary hypertension gas exchange severity (PH-GXS) score to assist with the assessment and monitoring of pulmonary arterial hypertension.

Woods PR, Taylor BJ, Frantz RP, Johnson BD.

Am J Cardiol. 2012 Apr 1;109(7):1066-72. doi: 10.1016/j.amjcard.2011.11.042. Epub 2012 Jan 14.

8.

Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study.

Peacock AJ, Crawley S, McLure L, Blyth K, Vizza CD, Poscia R, Francone M, Iacucci I, Olschewski H, Kovacs G, Vonk Noordegraaf A, Marcus JT, van de Veerdonk MC, Oosterveer FP.

Circ Cardiovasc Imaging. 2014 Jan;7(1):107-14. doi: 10.1161/CIRCIMAGING.113.000629. Epub 2013 Oct 30.

10.

Combination therapy in pulmonary arterial hypertension.

Pugh ME, Hemnes AR, Robbins IM.

Clin Chest Med. 2013 Dec;34(4):841-55. doi: 10.1016/j.ccm.2013.08.007. Epub 2013 Oct 17. Review.

PMID:
24267308
11.

Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral.

Badagliacca R, Pezzuto B, Poscia R, Mancone M, Papa S, Marcon S, Valli G, Sardella G, Ferrante F, Iacoboni C, Parola D, Fedele F, Vizza CD.

J Heart Lung Transplant. 2012 Apr;31(4):364-72. doi: 10.1016/j.healun.2011.12.011. Epub 2012 Jan 29.

PMID:
22289484
12.

Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.

McLaughlin VV.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:10-5.

PMID:
16919005
13.

Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.

Keir GJ, Walsh SL, Gatzoulis MA, Marino PS, Dimopoulos K, Alonso R, Raposeiras-Roubin S, Renzoni EA, Maher TM, Wells AU, Wort SJ.

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Jul 8;31(2):82-90.

PMID:
25078636
14.

The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension.

Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, Welte T, Hoeper MM.

Eur Respir J. 2012 Mar;39(3):589-96. doi: 10.1183/09031936.00092311. Epub 2011 Sep 1.

15.

Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.

Park MH.

Catheter Cardiovasc Interv. 2008 Feb 1;71(2):205-13. doi: 10.1002/ccd.21389. Review.

PMID:
18327839
16.

Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies.

Zijlstra WM, Douwes JM, Rosenzweig EB, Schokker S, Krishnan U, Roofthooft MT, Miller-Reed K, Hillege HL, Ivy DD, Berger RM.

J Am Coll Cardiol. 2014 May 27;63(20):2159-69. doi: 10.1016/j.jacc.2014.02.575. Epub 2014 Mar 26.

17.

Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.

de Jesus Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, Jain M, Bourge RC, Kudelko K, Spiekerkoetter E, Liu J, Hsi A, Zamanian RT.

Am J Cardiol. 2012 Nov 15;110(10):1546-50. doi: 10.1016/j.amjcard.2012.07.012. Epub 2012 Jul 30.

PMID:
22853986
18.

Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.

Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, Girgis RE.

Arthritis Rheum. 2009 Feb;60(2):569-77. doi: 10.1002/art.24267.

19.

Management of pulmonary arterial hypertension.

Judge EP, Gaine SP.

Curr Opin Crit Care. 2013 Feb;19(1):44-50. doi: 10.1097/MCC.0b013e32835c5137. Review.

PMID:
23242212
20.

Screening and treating pulmonary arterial hypertension in a tertiary hospital-based multidisciplinary clinic: the first 200 patients.

Low AJ, Fowler D, Manghani MK, Young I, Garsia R, Torzillo P, Youssef P, Celermajer DS.

Intern Med J. 2013 Jan;43(1):32-7. doi: 10.1111/j.1445-5994.2011.02624.x.

PMID:
22032309
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk